Literature DB >> 20652448

Allelic loss of 6q25-27, the PARKIN tumor suppressor gene locus, in cervical carcinoma.

S J Mehdi1, M S Alam, S Batra, M M A Rizvi.   

Abstract

Studies on loss of heterozygosity have been made for Parkin gene-specific microsatellite markers in malignancies like breast, ovary and lungs, and the results have shown a significant association. However, till date, there is no study with respect to Parkin gene-associated microsatellite markers in cervical cancer. The present study deals with the Parkin gene-associated microsatellite markers and the occurrence of its loss of heterozygosity in patients with human cervical cancer. DNA was isolated from the 105 cervical carcinoma samples and matched control specimens. Polymerase chain reaction was performed using primer specific for two intragenic markers D6S1599 and D6S305 present in Parkin introns 2 and 7, respectively, and one marker (D6S1008) at telomeric end and further electrophoresed on 8% denaturing polyacrylamide gel. Overall, 59 of 105 (56%) samples showed loss of heterozygosity in at least one locus in the region examined. The percentage of loss of heterozygosity for these markers ranged from 25% (D6S1008) to 48% (D6S305). Chi-square test was performed, and loss of heterozygosity was found significantly higher in both the intragenic markers (D6S1599 and D6S305) when compared with the locus at telomeric end (D6S1008) with P<0.05. These data argue that Parkin is a tumor suppressor gene whose inactivation may play an important role in the carcinoma of uterine cervix.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652448     DOI: 10.1007/s12032-010-9633-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  44 in total

1.  Identification and characterization of the human parkin gene promoter.

Authors:  A West; M Farrer; L Petrucelli; M Cookson; P Lockhart; J Hardy
Journal:  J Neurochem       Date:  2001-09       Impact factor: 5.372

2.  Point mutations (Thr240Arg and Gln311Stop) [correction of Thr240Arg and Ala311Stop] in the Parkin gene.

Authors:  N Hattori; H Matsumine; S Asakawa; T Kitada; H Yoshino; B Elibol; A J Brookes; Y Yamamura; T Kobayashi; M Wang; A Yoritaka; S Minoshima; N Shimizu; Y Mizuno
Journal:  Biochem Biophys Res Commun       Date:  1998-08-28       Impact factor: 3.575

3.  Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization.

Authors:  B C Bastian; P E LeBoit; H Hamm; E B Bröcker; D Pinkel
Journal:  Cancer Res       Date:  1998-05-15       Impact factor: 12.701

4.  Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix.

Authors:  A M Kersemaekers; M J van de Vijver; G G Kenter; G J Fleuren
Journal:  Genes Chromosomes Cancer       Date:  1999-12       Impact factor: 5.006

5.  Allelic deletion mapping on chromosome 6q and X chromosome inactivation clonality patterns in cervical intraepithelial neoplasia and invasive carcinoma.

Authors:  R Chuaqui; M Silva; M Emmert-Buck
Journal:  Gynecol Oncol       Date:  2001-03       Impact factor: 5.482

6.  Instability of chromosome 6 microsatellite repeats in human cervical tumors carrying papillomavirus sequences.

Authors:  F Kisseljov; L Semionova; E Samoylova; N Mazurenko; E Komissarova; V Zourbitskaya; T Gritzko; V Kozachenko; M Netchushkin; S Petrov; A Smirnov; A Alonso
Journal:  Int J Cancer       Date:  1996-12-20       Impact factor: 7.396

7.  Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer.

Authors:  I E Cooke; A N Shelling; V G Le Meuth; M L Charnock; T S Ganesan
Journal:  Genes Chromosomes Cancer       Date:  1996-04       Impact factor: 5.006

8.  Loss of heterozygosity at 6q is frequent and concurrent with 3p loss in sporadic and familial capillary hemangioblastomas.

Authors:  Sebsebe Lemeta; Lea Pylkkänen; Markku Sainio; Mika Niemelä; Sirkku Saarikoski; Kirsti Husgafvel-Pursiainen; Tom Böhling
Journal:  J Neuropathol Exp Neurol       Date:  2004-10       Impact factor: 3.685

9.  Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.

Authors:  Maria Cristina Picchio; Eric Santos Martin; Rossano Cesari; George Adrian Calin; Sai Yendamuri; Tamotsu Kuroki; Francesca Pentimalli; Manuela Sarti; Kristine Yoder; Larry R Kaiser; Richard Fishel; Carlo Maria Croce
Journal:  Clin Cancer Res       Date:  2004-04-15       Impact factor: 12.531

10.  Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.

Authors:  Selvaraju Veeriah; Barry S Taylor; Shasha Meng; Fang Fang; Emrullah Yilmaz; Igor Vivanco; Manickam Janakiraman; Nikolaus Schultz; Aphrothiti J Hanrahan; William Pao; Marc Ladanyi; Chris Sander; Adriana Heguy; Eric C Holland; Philip B Paty; Paul S Mischel; Linda Liau; Timothy F Cloughesy; Ingo K Mellinghoff; David B Solit; Timothy A Chan
Journal:  Nat Genet       Date:  2009-11-29       Impact factor: 38.330

View more
  14 in total

Review 1.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

Review 2.  Therapeutic effects of date fruits (Phoenix dactylifera) in the prevention of diseases via modulation of anti-inflammatory, anti-oxidant and anti-tumour activity.

Authors:  Arshad H Rahmani; Salah M Aly; Habeeb Ali; Ali Y Babiker; Sauda Srikar; Amjad A Khan
Journal:  Int J Clin Exp Med       Date:  2014-03-15

3.  Implication of alterations in Parkin gene among North Indian patients with colorectal cancer.

Authors:  Raj Ranjan Tiwari; Khushnuma Wahabi; Ahmad Perwez; Zafar Iqbal Bhat; Syed Shamimul Hasan; Sundeep Singh Saluja; Moshahid Alam Rizvi
Journal:  Turk J Gastroenterol       Date:  2020-03       Impact factor: 1.852

4.  Parkin gene alterations in ovarian carcinoma from northern Indian population.

Authors:  Syed Jafar Mehdi; Asgar Ali; M Moshahid Alam Rizvi
Journal:  Pathol Oncol Res       Date:  2011-01-10       Impact factor: 3.201

5.  Expressional evaluation of vascular endothelial growth factor (VEGF) protein in urinary bladder carcinoma patients exposed to cigarette smoke.

Authors:  Arshad Rahmani; Mohammad Alzohairy; Habeeb Khadri; Ashish K Mandal; Moshahid A Rizvi
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

6.  Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration.

Authors:  Sama F Sleiman; Brett C Langley; Manuela Basso; Jill Berlin; Li Xia; Jimmy B Payappilly; Madan K Kharel; Hengchang Guo; J Lawrence Marsh; Leslie Michels Thompson; Lata Mahishi; Preeti Ahuja; W Robb MacLellan; Daniel H Geschwind; Giovanni Coppola; Jürgen Rohr; Rajiv R Ratan
Journal:  J Neurosci       Date:  2011-05-04       Impact factor: 6.167

7.  Implication of androgen receptor in urinary bladder cancer: a critical mini review.

Authors:  Arshad H Rahmani; Mohammad Alzohairy; Ali Yousif Y Babiker; Amjad A Khan; Salah M Aly; Moshahid A Rizvi
Journal:  Int J Mol Epidemiol Genet       Date:  2013-09-12

8.  Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response.

Authors:  Conggang Zhang; Zeyu Liu; Eric Bunker; Adrian Ramirez; Schuyler Lee; Yinghua Peng; Aik-Choon Tan; S Gail Eckhardt; Douglas A Chapnick; Xuedong Liu
Journal:  J Biol Chem       Date:  2017-07-03       Impact factor: 5.157

9.  Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients.

Authors:  Rehana Qureshi; Himanshu Arora; Shilpi Biswas; Ahmad Perwez; Afreen Naseem; Saima Wajid; Gauri Gandhi; Moshahid Alam Rizvi
Journal:  Tumour Biol       Date:  2016-01-14

Review 10.  Parkin in Parkinson's Disease and Cancer: a Double-Edged Sword.

Authors:  Khushnuma Wahabi; Ahmad Perwez; Moshahid A Rizvi
Journal:  Mol Neurobiol       Date:  2018-01-18       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.